December 12, 2017
Two new studies published in Gut showed that the novel acid blocker vonoprazan effectively prevented ulcer recurrence in aspirin and NSAID users, and thus has the potential to become a new treatment option.
Vonoprazan (Takeda) is a potassium-competitive acid blocker approved in Japan for the treatment of acid-related diseases, with several clinical advantages over PPIs, according to Takashi Kawai, MD, of the endoscopy center at Tokyo Medical University Hospital, and colleagues. “For example, vonoprazan does not require an acidic environment for activation and is acid stable, eliminating the need for an enteric-coated formulation,” they wrote. Additionally, it works faster, and “provides potent and long-lasting inhibition of gastric acid secretion, and its efficacy is therefore expected to be superior to that of PPIs.”